Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients

Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients

The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.

Inclusion Criteria:

• Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy
• Age > 18 years
• ECOG PS 0-2.

Exclusion Criteria:

• Patients treated with irinotecan
• Lack of physical integrity of the upper gastrointestinal tract
• Patients with malabsorption syndrome
• Patients having inability to take oral medication
• Patients with poor performance status
• Patients with chronic diarrhea as ulcerative colitis or Crohn's disease